This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with
Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive
Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail email@example.com.